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Abstract
Background: Vancomycin is an antibiotic of growing importance in the treatment of hospital infections, with
particular emphasis on its value in the fight against methicillin-resistant Staphylococcus aureus. However its usage
profile must be evaluated to assure maximum benefit and minimum risk.
Findings: A cross-sectional retrospective study was carried out among inpatients that received vancomycin in a
Brazilian quaternary hospital. The occurrence of adverse reactions reported was evaluated in medical records
relating to patients taking vancomycin during a one year period. Males comprised 52% (95% CI: 41.7-60.2%) of the
sample population, with a mean age of 50.6 (95% CI: 47.2-54.0) years and mean treatment period of 9.7 (95% CI:
8.0-11.5) Days. It was verified that nephrotoxicity occurred in 18.4% (95% CI: 11.3-27.5) of patients, Red man
syndrome occurred in 2% (95% CI 0.2-7.2), while the occurrence of thrombocytopenia was 7.1% (95% CI: 2.9-14.2).
Conclusions: It may be noted that even after 50 years of use, adverse reactions associated with vancomycin
continue with high frequency, presenting a public health problem, especially considering its current use in cases of
multidrug resistant infections. In this context, we emphasize the importance of intensive pharmacovigilance in
hospital as a surveillance tool after drug approval by the sanitary authority.
Findings
Introduction
Vancomycin is a complex glycopeptide antibiotic with an
unusual structure and molecular mass of approximately
1500 Da. Vancomycin acts primarily inhibiting the cell-
wall biosynthesis. Its action against gram-positive cell
walls is related to the prevention of the incorporation of
N-acetylmuramic acid and N-acetylglucosamine into the
peptideoglycan matrix. Its therapeutic use against infec-
tions caused by gram-positive bacteria started in the
1950’s and it is still used currently. During the 1960’s and
70’s its use suffered a large decline, due to the high inci-
dence of adverse reactions and the introduction of semi-
synthetic penicillins with broadest spectrum of action in
the therapeutic arsenal [1]. However, the rapid develop-
ment of bacterial resistance to semisynthetic penicillin,
especially methicillin-resistant Staphylococcus aureus
(MRSA), led to the return of the use of vancomycin on a
large scale from the 1980’s.
During the following two decades, some studies showed
a possible link between the widespread use of vancomycin
and a rise in the incidence of adverse reactions, especially
nephrotoxicity [1], ototoxicity [2], thrombocytopenia [3,4],
epidermal necrosis [5], neutropenia [6], phlebitis [7], and a
pathology related to histamine release known as the red
man syndrome [8-10], which highlights the need for more
effective monitoring of the use of this antibiotic. The
reports of Enterococcus faecalis resistant to vancomycin
published since the 1990’s, and recently in Brazilian hospi-
tals, further emphasizes the need to rationalize the use of
this drug [11]. Others studies have been carried out in
order to confirm the safe use of vancomycin, as the recent
systematic review that compared vancomycin safety and
efficacy with the other available glycopeptide [12]. This
study showed the importance of producing more scientific
data on vancomycin ADR. Nevertheless, the severity of
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monitoring techniques employed and vancomycin’s effec-
tiveness when it is used [13]. Therefore, this study evalu-
ates the use of vancomycin and the prevalence of the main
adverse reactions in a large university hospital in quatern-
ary care.
Methods
Population studied
The retrospective cross-sectional study population con-
sisted of individuals who had used vancomycin during
the period of July 2003 to June 2004, as this data were
the most reliable in relation to the storage process and
accessible at the time of the study, while attending a uni-
versity hospital in Brazil. From the total of 350 patients
that utilized vancomycin during the study period, a
random sample was selected based on the sample size
estimation calculated by statcalc tool from epiinfo
®
(version 3.3.2), utilizing 95% of precision. The estimated
sample size was 122 patients. Based on that estimate, a
random sample of 131 patients was selected as the popu-
lation for this study. After applying the exclusion criteria,
98 medical records were included for analysis. The study
included all individuals older than 18 years, with use of
vancomycin confirmed by documentation in their medi-
cal records. It excluded mainly those individuals whose
records contained insufficient laboratory data to allow
assessment of presence or absence of adverse reactions.
Definitions
For measuring and comparing the data regarding the
exposure of vancomycin, we utilized as reference the
mean daily dose of the drug when used for its main
indication, being equal to 2 g of vancomycin [6]. Thus,
all the vancomycin exposure data were expressed as
grams of vancomycin. Adverse reactions were categor-
ized as: probable (event or laboratory test abnormality,
with reasonable time relationship to drug intake, unli-
kely to be attributed to disease or other drugs, response
to withdrawal clinically reasonable, rechallenge not
required); possible (event or laboratory test abnormality,
with reasonable time relationship to drug intake, could
also be explained by disease or other drugs, information
on drug withdrawal may be lacking or unclear); condi-
tional (event or laboratory test abnormality, more data
for proper assessment needed, or additional data under
examination); and uncertain (event or laboratory test
abnormality, with a time to drug that makes a relation-
ship improbable, but not impossible, disease or other
drugs provide plausible explanations) [14-16].
Ethics
In order to comply with regulations relating to Human
Research, requirements regarding the confidentiality and
secrecy of the information collected were adhered to.
The study was approved by the ethics committee of the
Faculty of Medicine of Federal University of Rio de
Janeiro, being filed under the number 115/04. The pro-
ject was approved on 9 September 2004.
Data Collection
A survey was structured through the analysis of the data
from the hospital IT system and the reports of the use
of antimicrobials archived by the committee of hospital
infection control, only standardized forms were used for
data collection, and the following variables referenced in
the literature were selected as relevant to the occurrence
of adverse drug reaction: age [17], sex, serum creatinine
[17], use of nephrotoxic drugs [18,19], hypoalbuminemia
[19], dose and reason for use. Signs and symptoms of
adverse reactions were evaluated using the criteria in
Table 1.
The standardized forms contained the following infor-
mation: Patient ID; date of birth; body weight; height;
sex; reason to utilize vancomycin; date of use; daily
dose; length of infusion; previous use of vancomycin;
laboratory data (total serum proteins; serum albumin;
hematocrit; total white blood cells count; neutrophils
count; serum creatinine; platelets); other drugs; ADR
description; concomitant diseases. The data were col-
lected by one researcher and checked by another to
maintain the quality of form filling.
As the cross-sectional design of study has not the abil-
ity to establish causality relationship, we screened every
detected ADR with two distinct algorithms Karch and
Lasagna algorithm and Naranjo & col algorithm, both
previously published and already established to classify
the probability of occurrence of an ADR, minimizing
the risk of bias during the ADR detection process
[14,15].
Data analysis
The analysis was performed by comparing the preva-
lence of adverse reactions between the various strata of
this subpopulation [20,21]. The database created to
manage the information collected during the hospital
records search was set using the epiinfo software version
3.3.2 (Centers for Disease Control and Prevention -
CDC, USA). The prevalence ratios were calculated by
comparing the prevalence of ADR in groups of patients
that were/were not exposed to specific risk factors
(other drugs, previous vancomycin use, and others).
These prevalence ratios were calculated using epiinfo
®
and compared utilizing chi square or the fisher exact
test.
Results and Discussion
Prevalence of Adverse Reactions for Vancomycin
The prevalence of adverse reactions to vancomycin
observed in medical records is presented in Table 2.
From the data collected it was found that 27.6% (95% CI:
19.0 - 37.5%) of the patients treated with vancomycin had
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use of this drug [2]. The prevalence of ADR to vancomy-
cin is alarming as these reactions may worsen the clinical
condition of patients which can often already be grave
and, in some cases, enhance the adverse effects of other
drugs. A direct comparison is difficult to be made
between the total prevalence of adverse reactions in the
present study and those in other previous reports, since
most previous reports set their focus on a specific adverse
reaction and not on a range of possible adverse reactions
associated with this drug.
The frequency of renal ADR of 18.4% (95% CI: 11.3 -
27.5%) was similar to the study of Farber & col, that
observed approximately 15% of patients suffering renal
adverse reactions [2]. The prevalence of renal ADR
observed is closer to the data for elderly patients, over 60
years, presented by Vance-Bryan [17]. The study published
by Rybak & col [19], establishes a prevalence of approxi-
mately 10% for this type of ADR. However, it should be
noted that the average age of the patients in our study was
around 50 years. The prevalence of this ADR is even more
important because it may impact on other drugs with pri-
marily renal elimination and also the loss in renal clear-
ance capacity may increase vancomycin drug plasma levels
[22,23], as it is mainly eliminated by renal filtration, wor-
sening the ADR. This fact reinforces the importance of
laboratory monitoring vancomycin use [13].
A significant finding of this study was that the preva-
lence of thrombocytopenia was 7.1% (95% CI: 2.9 -
14.2%). This value was discrepant with the fact that
thrombocytopenia has historically been regarded as a
rare adverse reaction to vancomycin [3,24]. Farber &
col. study do not even cite this ADR among those
observed [2]. The prevalence of neutropenia was 2% (0.2
- 7.2%) being consistent with studies carried out pre-
viously [2] including one cited by Rocha & col [7],
where both report an incidence close to 2%. It should
be noted that many of the neutropenia-type reactions in
patients studied in this research were excluded as ADRs
because patients were also using antineoplastic drugs
that may more frequently lead to the development of
this ADR [8], however case reports have increased [3,7]
and greater attention has been given to this ADR. In a
retrospective study with pediatric patients [25], throm-
bocytopenia corresponded to 26.3% of ADRs, and was
the second most prevalent ADR to vancomycin in that
study. More recently, the incidence of this ADR was stu-
died by monitoring patients treated with vancomycin
over a five year period and this corroborated the results
reported in the present study [26].
As the ADR most characteristic of vancomycin use,
the RMS, has received most attention in studies that
report the use of this drug. In the present study, the
prevalence of this ADR was 2% (95% CI: 0.2 - 7.2%), a
v a l u eq u i t ec l o s et ot h a tf o u n db yF a r b e r&c o l[ 2 ] ,
which was 3%. The retrospective study of children by
Hing & col [23] had a prevalence of about 2% for this
ADR, in addition to the study of Wallace & col [9],
Table 1 Criteria followed for evaluate signs and symptoms of adverse reactions
Adverse
symptoms/
reactions
Source Criteria
Phlebitis Medical records Indicated by medical personnel
Nephrotoxicity Medical records/
Laboratorial analysis
Serum creatinine concentrations of 0.5 mg/dl or 50% increase over the baseline, whichever is the
higher value
14
Neutropenia Medical records/
Laboratorial analysis
Neutrophil count below 1,000 cells per cm
3 of peripheral blood
1
Ototoxicity Medical records Indicated by medical personnel after audiometric evaluations and reports of hearing loss after
treatment, obtained by attending physicians in the process of anamnesis;
Thrombocytopenia Medical records/
Laboratorial analysis
Platelet count less than 100,000 per microliter of peripheral blood
Red man syndrome Medical records Indicated by attending physicians and reviewers, faced with the following standard of diagnosis:
flushing, itching, chest pain, muscle spasm or hypotension during infusion of vancomycin
Table 2 Prevalence of adverse reactions to vancomycin during the study period
Type of adverse reaction Number of patients Percentage 95% CI (%)
Nephrotoxicity 18 18.4 11.3 - 27.5
Neutropenia 2 2 0.2 - 7.2
Ototoxicity 1 1 0.0 - 5.6
Red Man Syndrome 2 2 0.2 - 7.2
Thrombocytopenia 7 7.1 2.9 - 14.2
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and 70-90% in healthy volunteers. Considering that the
occurrence of RMS is directly related to the rate of infu-
sion of vancomycin [20,22,23,27,28], the fact that 60% of
patients who used vancomycin had no information in
their records regarding the duration of infusion of van-
comycin solution shows that there is a dangerous lack
of concern or ignorance of this type of ADR and the
recommended method of drug administration.
Ototoxicity is an ADR that had a prevalence of 1%
(95% CI: 0 - 5.6%) with similar data presented by Farber
& col. This study has no recorded occurrence of phlebi-
tis. However the study of Farber & col [2] showed a pre-
valence of 13% of this ADR, being the second most
prevalent. In the study by Hing & col [23] it is pre-
sented, in conjunction with pain, as the most prevalent
ADR affecting 11% of patients treated with vancomycin.
A plausible reason for the low prevalence of ototoxicity
is the non-completion of routine audiometric tests in
hospitalized patients, which was the real measure of pre-
valence of this ADR [2].
Sample Characteristics and Vancomycin Exposure
Of the 131 selected patients, 98 were effectively ana-
lyzed, as the medical charts of 31 patients had inade-
quate records, especially regarding to the clinical
laboratory data, becoming impossible the verification of
signs and symptoms of ADR, and 2 patients were aged
less than 18 years, being therefore excluded from the
study. Table 3 shows the main characteristics of the
population studied and no evidence of clustering in the
extremes of age or by sex, which could suggest con-
founding factors for the prevalence estimate of ADR
[16,17].
T h ed a t aa n a l y s i s( T a b l e4 )o fi n i t i a lc r e a t i n i n ea n d
serum albumin showed that patients that presented with
ADRs did not show any laboratory data at the beginning
of treatment that would have identified them as a group
at risk of suffering adverse reactions [29].
The main reasons for the use of vancomycin among
the studied patients were sepsis 12.2% (95% CI: 6.5 -
20.4%), nosocomial pneumonia 12.2% (95% CI: 6.5 -
20.4%), catheter-associated infection 11.2% (95% CI: 5.7
- 19.2%) and blood culture with Gram positive cocci
11.2% (95% CI: 5.7 - 19.2%). Among patients who had
some type of adverse reaction associated with vancomy-
cin, the main reasons for using the drug were septic
shock 11.1% (95% CI: 2.4 - 29.2%), nosocomial pneumo-
nia 11.1% (95% CI: 2.4 - 29.2%), endocarditis 7.4% (95%
CI: 0.9 - 24.3%) and abdominal sepsis 7.4% (95% CI: 0.9
- 24.3%).
The analysis of the total doses of vancomycin pre-
sented in Table 4 shows that there is no significant dif-
ference in total dose of vancomycin administered to the
group of patients that did present with an ADR com-
pared to those that did not (p >0.05). The analysis of
average daily dose of vancomycin also showed no signif-
i c a n td i f f e r e n c eb e t w e e nt h ea v e r a g ed a i l yd o s eg i v e nt o
patients that did and those that did not present with an
ADR (p >0.05). Statistical analysis comparing the sub-
groups of ADR+ and ADR- patients as presented at
Table 4 did not present any statistically significant dif-
ference (P > 0.05).
Concurrent use of other antimicrobial drugs was also
evaluated, since some studies suggest synergism in their
ability to cause adverse reactions with vancomycin
[18,19,26,29,30]. It was found that cefepime, imipenem/
cilastatin and ciprofloxacin were the most commonly
used antibiotics in both groups of patients, those that
did and did not present with an ADR. Broad-spectrum
beta-lactam drugs were the most frequent antimicrobial
drugs used in both groups. The prevalence ratio was cal-
culated as an indicator of the synergistic effect of these
antibiotics, but none had a statistically significant
relation.
The rate of infusion of vancomycin is one of the fac-
tors classically associated with the occurrence of adverse
reactions [20]. It is recommended that the duration of
the solution infusion is not less than 60 min. Thus, the
duration of vancomycin solution infusion was included
in the analysis of the factors possibly associated with
ADRs, and this was categorized as greater than 60 min,
less than 60 min or without any record. However it was
not possible to ascertain any statistically significant rela-
tionship between duration of infusion and the occur-
rence of ADR. Another worrying fact was the absence of
records of the infusion rate of vancomycin solution in
62.24% of the prescriptions of the total population, a
fact that suggests that little importance is assigned to
t h es c i e n t i f i ce v i d e n c eo fah i g h e ri n c i d e n c eo fc u t a -
neous and systemic adverse reactions in patients with
infusion of vancomycin over periods of less than 60 min
[8,20,22].
This study is retrospective and only the adverse effects
reported in medical records could be evaluated. The
absence of data in the medical records could reflect a
practice of not reporting some types of ADR, considered
Table 3 Characteristics of patients evaluated
Characteristics Median Mean Mean 95% CI (%)
Age (years) 51.5 50.6 47.2 - 54.0
Treatment time (days) 7.0 9.7 8.0 - 11.5
Total Vancomycin dose (g) 24 18.3 12.4 - 23.8
Vancomycin Daily dose (g/day) 1.9 1.9 1.6 - 2.4
Initial creatinine (mg/dl) 1.0 2.0 1.5 - 2.5
Albumin (g/dl) 1.8 1.9 1.6 - 2.1
Statistical analysis was performed using Student’s t test.
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is a low prevalence in retrospective studies, necessitating
the implementation of prospective studies so that an
accurate incidence of such ADRs can be known.
The data presented in this paper demonstrate that the
adverse reactions to vancomycin remain a serious public
health problem, even after five decades of its inclusion
in antimicrobial therapy.
Taking into account the methodological differences
and characteristics of each population in previous stu-
dies, it can be seen that the ability to control the occur-
rences of these adverse reactions has not evolved much
during the last 20 years.
Conclusions
Despite the limitations of this study design, small sample
size and period of realization (2003-2004), especially
regarding the generalization of the results, this study
allowed a profile to be drawn showing the reality of the
use of vancomycin in a quaternary university hospital
with high demand. In assessing the prevalence of adverse
reactions to vancomycin it was possible to show that it is
still the case that many are not even perceived and even
less reported. A larger study, including a more diverse
study sample, is necessary in order to replicate the find-
ings and overcome the limitations of the present study. It
is also necessary to conduct a multiple variable analysis
[31] to disclose the possible interrelations between the
different exposure variables pointed by this study,
becoming possible to select groups of patients whose
vancomycin treatment should be more carefully moni-
tored. Despite the occurrence of ADRs due to vancomy-
cin use, it is an indispensable antibiotic to treat a broad
type of severe infections. However the healthcare profes-
sionals should be aware of the possibility of vancomycin
ADR, emphasizing the importance of pharmacovigilance
activities, including an active search for adverse reactions.
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